American Journal of Hematology / Oncology®
Assessing Current and Emerging Data Sets to Optimize Sequencing Considerations in ALK-Positive NSCLC

Release Date: December 6, 2016
Expiration Date: December 6, 2017
Media: Print with online posttest, evaluation, and request for credit

Overview

This activity is designed to inform physicians about current and emerging data sets in the context of optimizing sequencing considerations in patients with ALK-positive non-small cell lung cancer (NSCLC).

Instructions for Participation/How to Receive Credit:

  1. Read the article in its entirety.
  2. Use the QR code or type into your Web browser to access the posttest.
  3. Complete and pass the posttest with a score of 70% or higher.
  4. Complete the evaluation and request for credit.

Target Audience

This activity is directed toward medical oncologists, pulmonary care specialists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with lung cancer. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other healthcare providers interested in the treatment of lung cancer are also invited to participate.

Learning Objectives

After participating in this CME/CE activity, learners should be better prepared to:
  • Review current sequencing options in patients with ALK-positive NSCLC
  • Assess the potential impact of ongoing clinical trials/emerging data with respect to treatment sequencing in patients with ALK-positive lung cancer
  • Discuss the impact on clinical decision making that central nervous system metastases have on treatment and sequencing choices in ALK-positive NSCLC

The American Journal of Hematology/ Oncology® Editorial Board

Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.

Faculty

Dr. Ross Camidge, MD, PhD
University of Colorado Denver - School of Medicine
Aurora, Colorado
Disclosure: No relevant financial relationships with commercial interests to disclose.

 

Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of Physicians’ Education Resource®, LLC (PER®), and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.

It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity. 

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour. 

Acknowledgment of Commercial Support

This activity is funded by Physicians' Education Resource®, LLC.

Off-Label Disclosure and Disclaimer

This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed.The information provided in this CME/CE activity is for continuing medical and nursing education purposes only andis not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition. 

Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC. 

Contact information for questions about the activity:

Physicians’ Education Resource®, LLC 666 Plainsboro Road, Suite 356 Plainsboro, NJ 08536
Phone: (888) 949-0045
E-mail: info@gotoper.com 
 

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

 


PER® Practice Pulse
Practice Pattern Questions
How often do you attend society oncology/hematology meetings? (ASCO, ASH, SABCS)
Practice Pattern Questions
What is the most significant barrier to implementing new information in your clinical practice?

Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728
Filter By